Paul Scigalla
Chief Tech/Sci/R&D Officer bei GENELUX CORPORATION
Profil
Paul Scigalla is currently the Chief Medical Officer at Genelux Corp.
since 2011 and a Professor at Ruprecht-Karls-Universität Heidelberg since 1992.
He was previously the Executive Vice President at Sugen, Inc. from 1998 to 2001.
He also held the position of Chief Medical Officer at Nuevolution AB and Deutsche Biotech Innovativ AG.
Scigalla obtained his doctorate degree from Humboldt-Universität zu Berlin.
Aktive Positionen von Paul Scigalla
| Unternehmen | Position | Beginn |
|---|---|---|
| GENELUX CORPORATION | Chief Tech/Sci/R&D Officer | 01.09.2011 |
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 01.01.1992 |
Ehemalige bekannte Positionen von Paul Scigalla
| Unternehmen | Position | Ende |
|---|---|---|
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2001 |
| NUEVOLUTION AB (PUBL) | Chief Tech/Sci/R&D Officer | - |
| DEUTSCHE BIOTECH INNOVATIV AG | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Paul Scigalla
| Humboldt-Universität zu Berlin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GENELUX CORPORATION | Health Technology |
| DEUTSCHE BIOTECH INNOVATIV AG | Finance |
| Private Unternehmen | 2 |
|---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
